Eye, Ear, Nose and Throat Hospital Affiliated to Fudan University (Shanghai ENT Hospital)

It is a national key discipline and a national key clinical specialty; the Department of Otolaryngology-Head and Neck Surgery has been ranked first in the country for many consecutive years in the Fudan University Specialty Reputation List; it is a national-level referral center for difficult cases in ear and skull base surgery, cochlear implants, nasal and skull base surgery, head and neck tumors, and genetic therapy for hereditary deafness; it is benchmarked against the Johns Hopkins Otolaryngology-Head and Neck Surgery Center in the United States.

The Eye, Ear, Nose and Throat Hospital Affiliated to Fudan University is the first specialized eye, ear, nose and throat hospital in New China. Founded in 1952 by national first-class professors Hu Maolian and Guo Bingkuan, it is the only Grade III Class A eye, ear, nose and throat hospital directly under the National Health Commission. The hospital adheres to the motto of "Integrity, Unity, Pragmatism, and Innovation," aiming to become "a first-class specialized eye, ear, nose and throat hospital with international influence and an Asian medical center for ENT diseases." From Professors Hu Maolian and Guo Bingkuan, the founders of ENT and ophthalmology in China, to Professor Wang Zhengmin, the father of domestically produced cochlear implants and an academician of the Chinese Academy of Sciences, generations of ENT professionals have consistently upheld the hospital's motto and principles, practicing them diligently in every aspect of their work, from treating patients to conducting scientific research. It has now formed a "one hospital, two wings" development pattern - the Fenyang Campus and the Pujiang Campus constitute the two wings of clinical medical care, the Baoqing Road Branch Optometry Center and the Yaohua Road Branch Day Surgery Center form the two wings of specialized disease centers, and the Shaanxi South Road Science and Technology Innovation Center serves as a source of innovation.

Core business operational efficiency:

The hospital has 894 approved beds, with 755 actually in use. It currently has 2009 employees, including 1 academician of the Chinese Academy of Sciences, 6 recipients of the National Science Fund for Distinguished Young Scholars, 4 recipients of the National Science Fund for Excellent Young Scholars, 63 doctoral supervisors, and 60 master's supervisors. In 2024, the hospital saw over 3.29 million outpatient and emergency visits and performed over 193,000 surgeries, its medical reach extending throughout the country. The Department of Otolaryngology comprises five tertiary departments: Hearing and Speech Disorders, Neurosacral Surgery, Head and Neck Surgery, Rhinology, the Integrated Traditional Chinese and Western Medicine Rhinology Center, and Laryngology. It sees approximately 700,000 outpatient visits and performs over 15,000 surgeries annually.

Discipline Positioning and Core Strengths:

The hospital's Department of Otolaryngology is a national key clinical specialty and a national quality control center for otolaryngology-head and neck surgery. Its reputation has ranked first among national specialty rankings for over ten consecutive years, and it is one of the world's largest centers for the diagnosis, treatment, and research of otolaryngological-head and neck diseases. Its core advantages can be summarized as a four-dimensional integration: the historical foundation of the first specialized ENT hospital in New China × the world's first gene therapy for deafness and specialized surgical robots × international leadership in auditory medicine and nasal-cranial-base surgery × a complete industry-academia-research transformation through medical-engineering integration. The hospital boasts high-level research platforms, including the National Health Commission Key Laboratory of Hearing Medicine, the Chinese Academy of Medical Sciences' Innovative Unit for Endoscopic Nasal Skull Base Tumor Surgery, and the Shanghai Key Laboratory for Rare Disease Gene Editing and Cell Therapy (in preparation). It has also established research-oriented wards. Its landmark achievements include a Lancet cover article and the world's first clinical trial of gene therapy for congenital deafness.

It is a national key discipline and a national key clinical specialty; the Department of Otolaryngology-Head and Neck Surgery has been ranked first in the country for many consecutive years in the Fudan University Specialty Reputation List; it is a national-level referral center for difficult cases in ear and skull base surgery, cochlear implants, nasal and skull base surgery, head and neck tumors, and genetic therapy for hereditary deafness; it is benchmarked against the Johns Hopkins Otolaryngology-Head and Neck Surgery Center in the United States.

The Eye, Ear, Nose and Throat Hospital Affiliated to Fudan University is the first specialized eye, ear, nose and throat hospital in New China. Founded in 1952 by national first-class professors Hu Maolian and Guo Bingkuan, it is the only Grade III Class A eye, ear, nose and throat hospital directly under the National Health Commission. The hospital adheres to the motto of "Integrity, Unity, Pragmatism, and Innovation," aiming to become "a first-class specialized eye, ear, nose and throat hospital with international influence and an Asian medical center for ENT diseases." From Professors Hu Maolian and Guo Bingkuan, the founders of ENT and ophthalmology in China, to Professor Wang Zhengmin, the father of domestically produced cochlear implants and an academician of the Chinese Academy of Sciences, generations of ENT professionals have consistently upheld the hospital's motto and principles, practicing them diligently in every aspect of their work, from treating patients to conducting scientific research. It has now formed a "one hospital, two wings" development pattern - the Fenyang Campus and the Pujiang Campus constitute the two wings of clinical medical care, the Baoqing Road Branch Optometry Center and the Yaohua Road Branch Day Surgery Center form the two wings of specialized disease centers, and the Shaanxi South Road Science and Technology Innovation Center serves as a source of innovation.

Core business operational efficiency:

The hospital has 894 approved beds, with 755 actually in use. It currently has 2009 employees, including 1 academician of the Chinese Academy of Sciences, 6 recipients of the National Science Fund for Distinguished Young Scholars, 4 recipients of the National Science Fund for Excellent Young Scholars, 63 doctoral supervisors, and 60 master's supervisors. In 2024, the hospital saw over 3.29 million outpatient and emergency visits and performed over 193,000 surgeries, its medical reach extending throughout the country. The Department of Otolaryngology comprises five tertiary departments: Hearing and Speech Disorders, Neurosacral Surgery, Head and Neck Surgery, Rhinology, the Integrated Traditional Chinese and Western Medicine Rhinology Center, and Laryngology. It sees approximately 700,000 outpatient visits and performs over 15,000 surgeries annually.

Discipline Positioning and Core Strengths:

The hospital's Department of Otolaryngology is a national key clinical specialty and a national quality control center for otolaryngology-head and neck surgery. Its reputation has ranked first among national specialty rankings for over ten consecutive years, and it is one of the world's largest centers for the diagnosis, treatment, and research of otolaryngological-head and neck diseases. Its core advantages can be summarized as a four-dimensional integration: the historical foundation of the first specialized ENT hospital in New China × the world's first gene therapy for deafness and specialized surgical robots × international leadership in auditory medicine and nasal-cranial-base surgery × a complete industry-academia-research transformation through medical-engineering integration. The hospital boasts high-level research platforms, including the National Health Commission Key Laboratory of Hearing Medicine, the Chinese Academy of Medical Sciences' Innovative Unit for Endoscopic Nasal Skull Base Tumor Surgery, and the Shanghai Key Laboratory for Rare Disease Gene Editing and Cell Therapy (in preparation). It has also established research-oriented wards. Its landmark achievements include a Lancet cover article and the world's first clinical trial of gene therapy for congenital deafness.